Demystifying FluMist, a new intranasal, live influenza vaccine.
FluMist--a cold-adapted, live-attenuated, trivalent, intranasal influenza virus vaccine approved by the US Food and Drug Administration on June 17, 2003--has been shown to be safe and effective, but its role in the general prevention of influenza is yet to be defined. Intranasal administration is expected to be more acceptable than parenteral, particularly in children, but the potential for the shedding of live virus may pose a risk to anyone with a compromised immune system.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D017277:Drug Approval; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D007251:Influenza, Human / Q000517:prevention & control*; D008875:Middle Aged; D010353:Patient Education as Topic; D010612:Pharyngitis / Q000209:etiology; D012220:Rhinitis / Q000209:etiology; D012449:Safety; D014613:Vaccines, Attenuated / Q000008:administration & dosage
D007252:Influenza Vaccines; D014613:Vaccines, Attenuated